GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • American Association for Cancer Research (AACR)  (7)
  • 1
    In: Cancer Discovery, American Association for Cancer Research (AACR), Vol. 8, No. 12 ( 2018-12-01), p. 1548-1565
    Abstract: Malignant pleural mesothelioma (MPM) is a highly lethal cancer of the lining of the chest cavity. To expand our understanding of MPM, we conducted a comprehensive integrated genomic study, including the most detailed analysis of BAP1 alterations to date. We identified histology-independent molecular prognostic subsets, and defined a novel genomic subtype with TP53 and SETDB1 mutations and extensive loss of heterozygosity. We also report strong expression of the immune-checkpoint gene VISTA in epithelioid MPM, strikingly higher than in other solid cancers, with implications for the immune response to MPM and for its immunotherapy. Our findings highlight new avenues for further investigation of MPM biology and novel therapeutic options. Significance: Through a comprehensive integrated genomic study of 74 MPMs, we provide a deeper understanding of histology-independent determinants of aggressive behavior, define a novel genomic subtype with TP53 and SETDB1 mutations and extensive loss of heterozygosity, and discovered strong expression of the immune-checkpoint gene VISTA in epithelioid MPM. See related commentary by Aggarwal and Albelda, p. 1508. This article is highlighted in the In This Issue feature, p. 1494
    Type of Medium: Online Resource
    ISSN: 2159-8274 , 2159-8290
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2018
    detail.hit.zdb_id: 2607892-2
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 77, No. 13_Supplement ( 2017-07-01), p. 1706-1706
    Abstract: Aim: Neoantigens derived from tumor-specific somatic mutations are thought to be targets for antitumor immune responses. It has been reported that mutation/neoantigen burdens correlate with prognosis of certain cancers under checkpoint blockade immunotherapy. In clear cell ovarian carcinoma (CCOC), checkpoint inhibitors provided durable responses in a subset of patients. To test whether the same may apply in CCOC patients, who are not on immunomodulatory therapy, we investigated the number of mutations or neoantigens, and immune signature of CCOC by integrated molecular analysis. Methods: We performed exome sequencing and expression array for 74 CCOC patients. Candidate neoantigens derived from mutations were identified by MHC class I binding prediction algorism (NetMHCpan v 2.8). Immune signature was assessed by gene ontology and gene set enrichment analyses for immune cell lineage or molecule genes. We also analyzed their relationships with clinical outcomes. Results: Neither number of missense mutations nor neoantigens correlated with clinical outcomes in CCOC. However, we found neoantigen frequency defined here as the number of neoantigens per missense mutation correlated with clinical outcomes. A cox multivariate regression analysis demonstrated that high neoantigen frequency correlated with decreased progression free survival (PFS) and was an independent prognostic factor (p=0.032). Immune-related genes including those related to effector memory CD8 T cell were dominantly expressed in tumors with low neoantigen frequency. This may suggest that CD8 T cell-mediated immunity is constantly eliminating immunogenic subclones expressing neoantigens (immunoediting). In contrast, we observed increased ratio of CTLA-4 and PD-1 to CD8A expression in tumors with high neoantigen frequency. This may imply that restricted antitumor immunity by immunoinhibitory mechanism result in the limited immunoediting and poor prognosis Conclusions: Neoantigen frequency underlying immunoediting in CCOC is an independent prognostic factor for clinical outcome and may become a potential candidate biomarker for an immunomodulatory-based treatment. Citation Format: Hirokazu Matsushita, Kosei Hasegawa, Katsutoshi Oda, Shogo Yamamoto, Akira Nishijima, Yuichi Imai, Kayo Asada, Yuji Ikeda, Takahiro Karasaki, Keiichi Fujiwara, Hiroyuki Aburatani, Kazuhiro Kakimi. Neoantigen frequency as an independent prognostic factor in patients with clear cell ovarian carcinoma (CCOC) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 1706. doi:10.1158/1538-7445.AM2017-1706
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2017
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 78, No. 13_Supplement ( 2018-07-01), p. 5721-5721
    Abstract: Aim: Around 50% of high-grade serous ovarian carcinomas (HGSC) have deficiency in homologous recombination (HR) pathways. There has been increased evidence of benefit for the use of poly ADP ribose polymerase (PARP) inhibitors in a group of HGSC patients who especially have HR-deficient tumors. Therefore, it is needed to develop a new treatment strategy for the rest, an HR-proficient tumor. The aim of this study is to investigate immunological background of HR-proficient HGSC by integrated molecular analysis to explore the subset that would become candidates for immunotherapy such as immune checkpoint inhibitors. Methods: In total, 80 cases of HGSC were analyzed in this study. Exome and RNA sequencing were performed to identify germline and somatic mutations. Methylation arrays were also carried out to evaluate BRCA1 and RAD51C promoter methylation status. Predicted neoantigens derived from mutations were identified based on the MHC class I binding prediction algorithm NetMHCpan 2.8. Immune profile in the tumor was assessed by differential gene expression analysis and gene set enrichment analysis (GSEA) using RNA sequencing data. Neoantigen load, antigen presentation, immune profile and their relevance to clinical outcomes were also investigated. Results: Either BRCA1/2, RAD51C/D mutations, or BRCA1, RAD51C promoter methylation was defined as HR-deficient. A total of 34 (42.5%) and 46 (57.5%) patients were classified as having HR-deficient and HR-proficient tumors, respectively. As expected, the numbers of predicted neoantigens were lower in HR-proficient than HR-deficient tumors (p & lt;0.01). However, 40% of the patients with HR-proficient tumors still had high numbers of neoantigens and displayed better survival trend than those who had lower numbers of neoantigens. Incorporation of HLA-class I expression status in the analysis revealed that the patients who had both high neoantigen number and high HLA-class I expression showed improved survival in HR-proficient HGSC (p=0.02). GSEA demonstrated that the gene sets for effector memory CD8, TH1, and type I and type II interferon (IFN) responses were enriched in those patients. Conclusions: The number of neoantigens and HLA-class I expression characterized a subset of HR-proficient HGSC with improved prognosis and immunologically hot phenotype. This subset might be a candidate target for immune checkpoint inhibitors rather than PARP inhibitors. Citation Format: Hirokazu Matsushita, Kosei Hasegawa, Katsutoshi Oda, Shogo Yamamoto, Kayo Asada, Akira Yabuno, Akira Nishijima, Takahiro Karasaki, Yuji Ikeda, Keiichi Fujiwara, Hiroyuki Aburatani, Kakimi Kazuhiro. Neoantigen load and HLA-class I expression characterize a subset of HR-proficient high-grade serous ovarian carcinomas with favorable prognosis and T cell-inflamed phenotype [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 5721.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2018
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 74, No. 19_Supplement ( 2014-10-01), p. 4385-4385
    Abstract: Recently there have been several reports that the presence of cancer stem cells (CSCs) was related to the high refractoriness and infiltration in pancreatic cancer. Considering that microRNAs (miRNAs) are number-limited, functional nucleotides, those should be beneficial for efficient diagnostic and therapeutic approaches of pancreatic cancer. To identify the miRNAs, which play a critical role in the chemoresistance related to pancreatic CSCs, we performed sphere formation assay, as a tool for concentrating CSCs. It can enrich CSCs successfully in several types of cancer including pancreatic cancer. We use Panc1 cells and MiaPaCa2 cells as pancreatic cancer cell lines and established gemicitabine (GEM) resistant clones (Panc1-GRs) and Panc1 parental spheroid cells which were cultured in ES medium with EGF and FGF and ultra-low attachment plate (Panc1-P-Sp). The miRNA profilings between Panc1-GRs and Panc1-P-Sp were compared each other and miR-1246 was selected as a candidate miRNA related to the chemoresistance in pancreatic CSCs. In vitro the drug sensitivity of Panc1 and MiaPaCa2 was changed by miR-1246 transfection and the sphere formation ability of Panc1 was increased by pre-miR-1246 transfection. In pancreatic cancer cell line, Panc1, miR-1246 was up-regulated notably in the spheroid cells. This study revealed that it was related to not only chemoresistance but also stemness feature in pancreatic CSCs. In vivo it was confirmed that the miR-1246 could increase the tumorigenicity and reduced the drug sensitivity in NOD/SCID mice in which Panc1 cells were injected. Subsequently we focused on the molecular targets regulated by miR-1246. Because they link with elucidation for the mechanism through which miR-1246 adds chemoresistance to Panc1 cells. Using Target Scan, which can predict the candidates, 178 genes were selected. 7 genes related to malignant potential, REPS2, CCNG2, GRHL1, UNC5B, NEO1 and ZFP36L1 from previous reports were chosen. Among them, we focused on CCNG2 for further analysis. siRNA for CCNG2 was used to validate its involvement in the resistance to gemcitabine. Knockdown of CCNG2 was confirmed by western blot analysis. The MTT assay demonstrated that transfection of siCCNG2 enhanced the resistance of Panc1-P to gemcitabine but did not change the sphere formation ability. In conclusion, we demonstrated in the present study that miR-1246 inhibited the anti-cancer effect of gemcitabine in pancreatic cancer cells and that CCNG2 mediated this effect. The response to gemcitabine in Panc1 cells was controlled by genetic manipulation of miR-1246 and CCNG2. In addition, in vivo examination revealed that miR-1246 could change the drug sensitivity of pancreatic cancer cell tumor. Considered together, the results suggest that the anti-sense of miR-1246 could be a new therapy targeting CSCs in pancreatic cancer. Citation Format: Shinichiro Hasegawa, Ishii Hideshi, Hidetoshi Eguchi, Shogo Kobayashi, Hiroshi Wada, Naoki Hama, Yoshito Tomimaru, Kawamoto Koichi, Masamitsu Konno, Hisataka Ogawa, Shimpei Nishikawa, Yoshihiro Kano, Yoshihiro Kano, Takahito Fukusumi, Atsushi Hamabe, Takenori Nishimura, Kunihiko Hinohara, Taroh Satoh, Noriko Gotoh, Hiroaki Nagano, Yuichiro Doki, Masaki Mori. Identification of the crucial microRNA, miR-1246 related to the chemoresistance and stemness in pancreatic cancer for new targeting therapy. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 4385. doi:10.1158/1538-7445.AM2014-4385
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2014
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 5
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 73, No. 8_Supplement ( 2013-04-15), p. 4897-4897
    Abstract: Background. Pancreatic adenocarcinoma is a highly lethal disease, which is usually diagnosed in advanced stages for which there are little or no effective therapies. It has the worst prognosis of any major malignancy (3% 5-year survival) and is the fourth most common cause of cancer death yearly in the United States. Recently there have been several reports that the presence of cancer stem cells (CSCs) was related to the high refractoriness in pancreatic cancer. CSCs have two characteristics, self-renewal and differentiation, for maintenance of cancer tissues (Nature, 2001). Given that chemotherapies target generally against differentiated non-CSCs, small populations of CSCs survive and the recurrence of tumor growth will occur. Nevertheless, the underlined mechanism, which links between chemoresistance and stemness, remains to be elucidated. Considering that microRNAs are number-limited, functional nucleotides, those should be beneficial for efficient diagnostic and therapeutic approaches of pancreatic cancer. Matherials and Methods. Pancreatic cancer Panc1 cells were cultured in the medium containing increasing amounts of gemcitabine (GEM) to obtain several GEM-resistant clones. To identify the microRNAs, which play a critical role in the chemoresistance in pancreatic CSCs, we performed the serum-free floating culture of embryoid body-like structures by quick re-aggregation method (SFEBq), as a tool for separating CSCs; The SFEBq is the method for culture and concentration of neural stem cells, which can concentrate CSCs successfully in several types of cancer. The chemoresistance was studied by the MTT assay. RNAs were extracted, the genome-wide transcriptome was identified and networks were studied between stemness and chemoresistance. Results. The study of original Panc1 cells and four representative, independent GEM-resistant clones (R1, R2, R3 and R4) allowed the identification of CSC-specific and GEM-specific signal transduction pathways. The data were verified among four resistant clones. By utilizing specific inhibitors including small-molecule compounds and anti-microRNAs, we studied the network cross-talking CSCs and chemoresistance. Even if the SFEBq-enriched CSC clones were not exposed to GEM, their similarity to chemo-specific pathway reinforces that the small populations of CSCs would pre-exist as an innate resistance before treatment in patients. Such cross-talking pathway would be eligible to sensitize pancreatic cancer to chemotherapy, and to eradicate tumors. Conclusion. The data demonstrate the successful molecular dissection of stemness and chemoresistant pathways, and the present study provides the rationale for novel therapeutic approaches such as modified nucleotide medicines to target the pre-existing CSCs. Citation Format: Shinichiro Hasegawa, Hideshi Ishii, Shimpei Nishikawa, Hidetoshi Eguchi, Shogo Kobayashi, Hiroshi Wada, Naoki Hama, Hirofumi Akita, Koichi Kawamoto, Masamitsu Konno, Hisataka Ogawa, Katsuya Ohta, Yoshihiro Kano, Takahito Fukusumi, Atsushi Hamabe, Takenori Nishimura, Kunihiko Hinohara, Taroh Satoh, Noriko Gotoh, Yuichiro Doki, Masaki Mori, Hiroaki Nagano. Identification of microRNA networks in pancreatic cancer stem cells. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 4897. doi:10.1158/1538-7445.AM2013-4897
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2013
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 6
    In: Clinical Cancer Research, American Association for Cancer Research (AACR), Vol. 11, No. 7 ( 2005-04-01), p. 2620-2624
    Abstract: Purpose: We investigated single-nucleotide polymorphisms of the cytidine deaminase gene (CDA), which encodes an enzyme that metabolizes gemcitabine, to clarify the relationship between the single-nucleotide polymorphism 208G & gt;A and the pharmacokinetics and toxicity of gemcitabine in cancer patients treated with gemcitabine plus cisplatin. Experimental Design: Six Japanese cancer patients treated with gemcitabine plus cisplatin were examined. Plasma gemcitabine and its metabolite 2′,2′-difluorodeoxyuridine were measured using an high-performance liquid chromatography method, and the CDA genotypes were determined with DNA sequencing. Results: One patient, a 45-year-old man with pancreatic carcinoma, showed severe hematologic and nonhematologic toxicities during the first course of chemotherapy with gemcitabine and cisplatin. The area under the concentration-time curve value of gemcitabine in this patient (54.54 μg hour/mL) was five times higher than the average value for five other patients (10.88 μg hour/mL) treated with gemcitabine plus cisplatin. The area under the concentration-time curve of 2′,2′-difluorodeoxyuridine in this patient (41.58 μg hour/mL) was less than the half of the average value of the five patients (106.13 μg hour/mL). This patient was found to be homozygous for 208A (Thr70) in the CDA gene, whereas the other patients were homozygous for 208G (Ala70). Conclusion: Homozygous 208G & gt;A alteration in CDA might have caused the severe drug toxicity experienced by a Japanese cancer patient treated with gemcitabine plus cisplatin.
    Type of Medium: Online Resource
    ISSN: 1078-0432 , 1557-3265
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2005
    detail.hit.zdb_id: 1225457-5
    detail.hit.zdb_id: 2036787-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 7
    In: Cancer Prevention Research, American Association for Cancer Research (AACR), Vol. 8, No. 6 ( 2015-06-01), p. 492-501
    Abstract: Loss of parietal cells initiates the development of spasmolytic polypeptide–expressing metaplasia (SPEM), a precancerous lesion in stomach. CD44 variant (CD44v) that enhances the ability to defend against reactive oxygen species (ROS) in epithelial cells is expressed de novo in SPEM of K19-Wnt1/C2mE mice, a transgenic model of gastric tumorigenesis, and is required for the efficient development of SPEM and gastric tumor in these animals. The role of ROS and its downstream signaling in CD44-dependent gastric tumorigenesis has remained unknown, however. With the use of the K19-Wnt1/C2mE mouse, we now show that parietal cells in the inflamed stomach are highly sensitive to oxidative stress and manifest activation of p38MAPK signaling by ROS. Oral treatment with the antioxidant ascorbic acid or genetic ablation of the Ink4a/Arf locus, a major downstream target of ROS-p38MAPK signaling, inhibited parietal cell loss and the subsequent gastric tumorigenesis. Our results indicate that signaling activated by oxidative stress in parietal cells plays a key role in CD44-dependent gastric tumorigenesis. Cancer Prev Res; 8(6); 492–501. ©2015 AACR.
    Type of Medium: Online Resource
    ISSN: 1940-6207 , 1940-6215
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2015
    detail.hit.zdb_id: 2422346-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...